by Pulmonary edema refers to the accumulation of fluid in the air spaces and tissues of the lungs. It leads to difficulties in breathing and shortness of breath due to tissue inflammation or injuries to the lungs. Several cardiovascular and lung disorders result in pulmonary edema such as congestive heart failure (CHF), acute respiratory distress syndrome (ARDS), pneumonia, drowning etc. Increasing prevalence of such life-threatening diseases around the world is driving the need for effective pulmonary edema therapeutics. For instance, in the U.S approximately 6.5 million people suffer from heart failure and over US$ 30 billion is spent annually on heart failure related medical costs.
The global pulmonary edema therapeutics market offers a wide range of treatment drugs and devices. Drugs such as diuretics, vasodilators, inotropic agents etc that reduce fluid accumulation and tissue swelling are widely used. Novel formulations including inhaled versions of these drugs are being developed for faster symptom relief. Mechanical ventilators and non-invasive ventilation devices are commonly used to enhance oxygen delivery and reduce respiratory workload during critical edema episodes.
The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the pulmonary edema therapeutics market is the emergence of innovative inhalable therapies. Companies are developing formulations such as inhaled diuretics and vasodilators that can deliver drugs directly to the lungs. This enhances the bioavailability and response rate compared to traditional oral or injectable routes. For instance, United Therapeutics Corporation offers an inhaled vasodilator Treprostinil (Tyvaso) for pulmonary hypertension associated pulmonary edema. Such targeted therapies allow lower drug dosage requirements and reduce systemic side effects. They have the potential to become first-line options for edema management in future.
Porter’s Analysis
Threat of new entrants: Low, due to high capital requirements and patent protections of existing drugs.
Bargaining power of buyers: Moderate, as few therapeutic options exist and treatment is essential. However, buyers can negotiate lower prices.
Bargaining power of suppliers: Moderate, as suppliers have some differentiated products but also face pressure to reduce costs.
Threat of new substitutes: Low, as few substitution options exist for treating pulmonary edema.
Competitive rivalry: High, as major players compete on new drug development and pricing.
Key Takeaways
The Global Pulmonary Edema Therapeutics Market is expected to witness high growth. The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030.
North America holds the largest share of the market currently due to high healthcare spending and presence of key players in the region. Europe is also expected to show significant growth during the forecast period supported by growing older population and increased funding for healthcare services. The Asia Pacific region is anticipated to grow at the fastest pace owing to rising patient population, growing medical tourism, increased healthcare spending, and growing awareness.
Key players: Key players operating in the Pulmonary Edema Therapeutics Market are Crayola LLC, Faber-Castell AG, Sargent Art, Reeves (Colart Group), Liquitex (Colart Group), Sax Arts & Crafts, Prang (Dixon Ticonderoga Company), RASCHER GmbH, Richeson Art Materials, Jovi S.L. These players are focusing on new product launches and expansion strategies to gain higher market shares.
